Dynavax Technologies Corporation Stock News

Edgewise (EWTX) stock gains on upbeat interim results from the ARCH study of its lead candidate EDG-5506 in adults with Becker Muscular Dystrophy (BMD).

In the latest trading session, Dynavax Technologies (DVAX) closed at $11.78, marking a +1.12% move from the previous day.

Bristol Myers (BMY) secures an FDA nod for Sotyktu to treat adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.

Regeneron (REGN) stock jumps as aflibercept 8 mg with 12- and 16-week dosing regimens in patients with DME and wAMD meet primary goals.

Exelixis (EXEL) announces positive detailed results on the triplet combination study of Cabometyx, Opdivo and Yervoy.

Gilead (GILD) breast cancer drug Trodelvy demonstrates a statistically significant and clinically meaningful improvement of 3.2 months in overall survival compared to chemotherapy.

Spero (SPRO) surges on achieving common ground with the FDA on the regulatory path forward for tebipenem HBr.

Gilead (GILD) breast cancer drug Trodelvy shows efficacy across HER2-low and IHC0 status in pre-treated metastatic breast cancer patients.

Jounce Therapeutics (JNCE) declines as its mid-stage study, SELECT, evaluating vopratelimab in lung cancer patients, fails to meet the primary endpoint.

Novartis (NVS) strengthens its oncology portfolio with EC approval for its chronic myeloid leukemia drug, Scemblix.

The heavy selling pressure might have exhausted for Dynavax Technologies (DVAX) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Stree

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest

When a stock breaks out above the 20-day simple moving average, good things could be on the horizon. How should investors react?

The company delivered resounding beats on both the top and bottom lines in the second quarter.

Dynavax Technologies (DVAX) delivered earnings and revenue surprises of 290.91% and 73.80%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?